Biomaterial scaffolds for treating osteoporotic bone.
Healing fractures resulting from osteoporosis or cancer remains a significant clinical challenge. In these populations, healing is often impaired not only due to age and disease, but also by other therapeutic interventions such as radiation, steroids, and chemotherapy. Despite substantial improvements in the treatment of osteoporosis over the last few decades, osteoporotic fractures are still a major clinical challenge in the elderly population due to impaired healing. Similar fractures with impaired healing are also prevalent in cancer patients, especially those with tumor growing in bone. Treatment options for cancer patients are further complicated by the fact that bone anabolic therapies are contraindicated in patients with tumors. Therefore, many patients undergo surgery to repair the fracture, and bone grafts are often used to stabilize orthopedic implants and provide a scaffold for ingrowth of new bone. Both synthetic and naturally occurring biomaterials have been investigated as bone grafts for repair of osteoporotic fractures, including calcium phosphate bone cements, resorbable polymers, and allograft or autograft bone. In order to re-establish normal bone repair, bone grafts have been augmented with anabolic agents, such as mesenchymal stem cells or recombinant human bone morphogenetic protein-2. These developing approaches to bone grafting are anticipated to improve the clinical management of osteoporotic and cancer-induced fractures.
Department of Veterans Affairs: Tennessee Valley Healthcare System (VISN 9), Nashville, USA, julie.sterling@vanderbilt.edu.
Julie A
JA
Sterling
Scott A
SA
Guelcher
D001672:Biocompatible Materials / Q000627:therapeutic use; D055396:Bone Morphogenetic Protein 2 / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000150:complications / Q000556:secondary*; D016025:Bone Transplantation / Q000379:methods*; D005592:Fracture Fixation / Q000379:methods*; D005598:Fractures, Spontaneous / Q000209:etiology / Q000628:therapy*; D006801:Humans; D009984:Orthopedic Fixation Devices; D010024:Osteoporosis / Q000628:therapy*; D058866:Osteoporotic Fractures / Q000628:therapy*; D010281:Parathyroid Hormone / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D054457:Tissue Scaffolds; D016212:Transforming Growth Factor beta / Q000627:therapeutic use*
D001672:Biocompatible Materials; D055396:Bone Morphogenetic Protein 2; D010281:Parathyroid Hormone; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2